KALA BIO (KALA) Projected to Post Quarterly Earnings on Tuesday

Key Points

• KALA BIO is set to release its Q2 2025 earnings on August 5th, with analysts estimating earnings of ($1.82) per share for the quarter.
• The company's stock has experienced significant volatility, opening at $7.93 and previously reaching a twelve-month high of $11.20.
• Several analysts have recently revised their ratings on KALA BIO, with Wall Street Zen upgrading to a "hold" and Oppenheimer maintaining an "outperform" rating with a target price of $15.00.

KALA BIO (NASDAQ:KALA - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($1.82) per share for the quarter.

KALA BIO Trading Up 10.8%

NASDAQ KALA traded up $0.73 during trading hours on Friday, hitting $7.50. The company's stock had a trading volume of 138,258 shares, compared to its average volume of 216,393. The stock has a fifty day moving average of $5.17 and a 200 day moving average of $5.66. KALA BIO has a twelve month low of $2.92 and a twelve month high of $11.20. The firm has a market capitalization of $48.38 million, a P/E ratio of -0.91 and a beta of -1.81. The company has a quick ratio of 1.99, a current ratio of 1.99 and a debt-to-equity ratio of 3.19.

Insider Activity

In other news, Director Mark T. Iwicki sold 13,227 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $4.01, for a total transaction of $53,040.27. Following the completion of the sale, the director owned 258,433 shares of the company's stock, valued at $1,036,316.33. This represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 41,335 shares of company stock worth $162,876 over the last ninety days. 8.32% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. Woodline Partners LP acquired a new position in shares of KALA BIO, Inc. (NASDAQ:KALA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 258,766 shares of the company's stock, valued at approximately $1,483,000. Woodline Partners LP owned approximately 4.01% of KALA BIO as of its most recent SEC filing. Hedge funds and other institutional investors own 24.61% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on KALA shares. Oppenheimer restated an "outperform" rating and issued a $15.00 price objective on shares of KALA BIO in a report on Monday, June 2nd. LADENBURG THALM/SH SH assumed coverage on shares of KALA BIO in a research note on Friday, July 11th. They issued a "buy" rating and a $12.00 target price for the company. Wall Street Zen raised shares of KALA BIO from a "sell" rating to a "hold" rating in a research note on Monday, July 28th. Finally, HC Wainwright lowered their target price on shares of KALA BIO from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, May 23rd.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.